Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness

Compelling evidence shows that progestins regulate breast cancer growth. Using preclinical models, we demonstrated that antiprogestins are inhibitory when the level of progesterone receptor isoform A (PR-A) is higher than that of isoform B (PR-B) and that they might stimulate growth when PR-B is pre...

Descripción completa

Detalles Bibliográficos
Autores: Rojas, Paola Andrea, May, Maria, Sequeira, Gonzalo Ricardo, Elia, Andres Maximiliano, Alvarez, Michelle, Martínez, Paula, González, Pedro, Hewitt, Stephen, He, Xiaping, Perou, Charles M., Molinolo, Alfredo, Gibbons, Luz, Abba, Martín Carlos, Gass, Hugo, Lanari, Claudia Lee Malvina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/24588
Acceso en línea:http://hdl.handle.net/11336/24588
Access Level:acceso abierto
Palabra clave:Receptor de Progesterona
Antiprogestageno
Cancer de Mama
Isoforma A
Breast Neoplasms
Progestins
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
Descripción
Sumario:Compelling evidence shows that progestins regulate breast cancer growth. Using preclinical models, we demonstrated that antiprogestins are inhibitory when the level of progesterone receptor isoform A (PR-A) is higher than that of isoform B (PR-B) and that they might stimulate growth when PR-B is predominant. The aims of this study were to investigate ex vivo responses to mifepristone (MFP) in breast carcinomas with different PR isoform ratios and to examine their clinical and molecular characteristics.

Similares en LA Referencia